From Medscape Oncology

Medscape Medical News from the:

American Society of Hematology (ASH) 52nd Annual Meeting

December 04 - 07, 2010; Orlando, Florida

This coverage is not sanctioned by, nor a part of, the American Society of Hematology.


Top News From ASH 2010: Slideshow
Nilotinab shows 3-year durability in PH+CML, brentuximab "amazing" for refractory Hodgkin's lymphoma, and rituximab beats "watch and wait" for asymptomatic follicular lymphoma.

Conference News

Medscape Oncology©  WebMD, LLC

Medscape Oncology Insights

ASH Wrap-up: Lymphoma and Leukemia -- The Take-Home Message  Bruce D. Cheson, MD; Jorge Cortes, MD; John P. Leonard, MD

Hodgkin Lymphoma: New Drug Breakthroughs
Bruce D. Cheson, MD;
Nancy L. Bartlett, MD

NonHodgkin Lymphoma: New Drug Combinations
Bruce D. Cheson, MD;
John P. Leonard, MD

Ponatinib: The Real Deal for Refractory CML?
Bruce D. Cheson, MD;
Jorge Cortes, MD

Multiple Myeloma: New Agents and Novel Combination Treatments
Paul G. Richardson, MD